Esperion Therapeutics (ESPR) Proxy filing summary

Executive summary

• A special meeting is called for shareholders to vote on a proposed merger where shareholders will receive $3.16 per share in cash and one contingent value right (CVR) per share, with potential additional payments based on future product sales milestones.

• The merger is with Essence Parent Inc., an affiliate of ArchiMed SAS, and Essence MergerCo Inc., with the company becoming a wholly owned subsidiary if approved.

• The board unanimously recommends voting in favor of the merger, the advisory compensation proposal, and the adjournment proposal.

• The merger consideration was deemed fair from a financial point of view by Centerview Partners LLC, the company’s financial advisor.

Voting matters and shareholder proposals

• Shareholders will vote on: (1) adoption of the merger agreement, (2) advisory (non-binding) approval of executive compensation related to the merger, and (3) adjournment of the meeting if more votes are needed.

• Approval of the merger requires a majority of outstanding shares; the other proposals require a majority of votes cast.

• Directors and executive officers collectively own about 1.8% of shares and are expected to vote in favor.

• Shareholders who dissent may seek appraisal rights under Delaware law.

Board of directors and corporate governance

• The board conducted a thorough review of strategic alternatives and engaged in extensive negotiations with ArchiMed and other potential acquirers.

• The board considered the certainty and premium of the offer, the opportunity for additional value via CVRs, and the risks of remaining independent.

• The board’s decision was supported by a fairness opinion and a process involving outreach to multiple potential buyers.